Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Mayo Stephen, holds the title of Director at Sarepta Therapeutics, Inc..
On 2026-03-12, the insider transacted 7,239 shares.The shares were transacted at a weighted average price of $17.02 per share, resulting in a total market-relevant value of $123K.
Mayo Stephen (Director) sold $123K of $SRPT
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.